Study Of Intraperitoneal EGEN-001 Administered In Combination With Pegylated Liposomal-Doxorubicin In Patients With Recurrent Or Persistent Epithelial Ovarian Fallopian Tube Or Peritoneal Cancer

  • STATUS
    Recruiting
  • participants needed
    18
  • sponsor
    EGEN, Inc.
Updated on 8 November 2020
doxorubicin
doxil
peritoneal cancer
intraperitoneal chemotherapy

Summary

Pegylated liposomal doxorubicin (PLD; e.g., Doxil®, Lipodox™) will be administered intravenously on Day 1 and EGEN-001 will be administered intraperitoneally on Day 1, 8, 15, and 22 of a 28-day cycle to determine: - The maximum tolerated dose (MTD) and dose limiting toxicities (DLTs) of EGEN-001 when administered in combination with pegylated liposomal doxorubicin (PLD; Doxil®, Lipodox™), every 28 days and the associated DLTs based on adverse events that occur in cycle 1 for this combination in women with recurrent or persistent, epithelial ovarian, fallopian tube or primary peritoneal cancer. - The tolerability of the combination at the MTD of EGEN-001 assessed in combination with PLD. - The recommended phase II dose (RP2D) of EGEN-001 in combination with PLD.

Details
Condition Fallopian Tube Cancer
Treatment EGEN-001 (IL-12 PLASMID FORMULATED WITH LIPOPOLYMER), Pegylated Liposomal Doxorubicin (PLD), Doxil And Lipodox
Clinical Study IdentifierNCT01673477
SponsorEGEN, Inc.
Last Modified on8 November 2020

Eligibility

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar
Name

Primary Contact

site
Name

0/250
Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note